Fidson leads Nigeria’s pharmaceutical sector in first quarter of 2026
Fidson Healthcare Plc has emerged as the dominant performer in Nigeria’s pharmaceutical sector during the first quarter of 2026, according to Premium Times Nigeria. The company, listed on the Nigerian Exchange, was reported to have outpaced its peers in the industry over the three-month period, reinforcing its position as one of the country’s leading drug manufacturers.
Nigeria’s pharmaceutical industry has long grappled with a heavy dependence on imported medicines, a situation that has repeatedly drawn attention from regulators and policymakers concerned about supply security and foreign exchange pressures. In recent years, local manufacturers such as Fidson have expanded their production capacity, working under the oversight of the National Agency for Food and Drug Administration and Control to meet domestic demand for essential drugs. The sector’s performance is closely watched by investors, given that healthcare stocks represent a meaningful segment of the Nigerian Exchange.
Founded in Lagos in 1995, Fidson has grown into one of the most recognisable names in Nigeria’s generics market, producing a wide range of pharmaceutical products for local distribution. Its rise in quarterly rankings reflects both the company’s commercial strategy and the broader push by Nigerian authorities to strengthen local drug manufacturing as part of efforts to reduce import reliance. Premium Times Nigeria reported that Fidson’s leadership in the sector underscores the growing competitiveness of indigenous pharmaceutical firms operating in Africa’s largest economy.
Sources
This report was written from coverage published by the following news organisations. Follow the links for the original reporting.
- Premium Times Nigeria — Fidson dominates Nigeria’s Pharma sector first-quarter 2026
